Role of B7-CD28/CTLA-4 costimulation and NF-kappa B in allergen-induced T cell chemotaxis by IL-16 and RANTES.
The mechanisms that cause T cell recruitment into inflamed airways of asthmatic individuals are poorly understood. It has been shown previously that both natural exposure to allergen and challenge in the laboratory induce T cell accumulation in the bronchial mucosa of sensitized asthmatics. To study the mechanisms involved in this process, we have used an explant model in which bronchial biopsies taken from mild atopic asthmatic volunteers during fiberoptic bronchoscopy were stimulated in culture for 24 h by the common aeroallergen house dust mite (Dermatophagoides pteronyssinus (Der p)). Analysis of culture supernatants showed that stimulation with Der p significantly enhanced both the generation of T cell chemotactic activity by the mucosal tissue, as assayed in microchemotaxis chambers, and the production of IL-16 and RANTES. Neutralization experiments showed that IL-16 contributed more to the chemotactic activity than RANTES. The fusion protein CTLA-4-Ig, blocking B7:CD28 costimulation, and dexamethasone both significantly reduced the ex vivo production of chemotactic activity and release of IL-16 and RANTES. The proteasome inhibitor Cbz-Ile-Glu(OtBu)-Ala-leucinal also had a significant inhibitory effect on T cell chemotactic activity and IL-16 but not RANTES generation, indicating a role for nuclear factor NF kappa B activation. These results indicate that allergen stimulates cells within the bronchial mucosa to increase IL-16 and RANTES release, both of which contribute to T cell accumulation in asthmatic airways. The allergen-induced chemotactic activity is dependent on cell activation via CD28 and involves, at least partly, NF-kappa B.
Hidi
R
R
Division of Respiratory Cell and Molecular Biology, University Medicine, Southampton University General Hospital, United Kingdom.
Riches
V
V
Al-Ali
M
M
Cruikshank
W W
WW
Center
D M
DM
Holgate
S T
ST
Djukanovic
R
R
D000069594:Abatacept; D000328:Adult; D000485:Allergens / Q000276:immunology; D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D015703:Antigens, CD; D039741:Antigens, Dermatophagoides; D000943:Antigens, Differentiation / Q000502:physiology*; D001249:Asthma / Q000276:immunology / Q000378:metabolism; D018122:B7-1 Antigen / Q000502:physiology*; D001980:Bronchi / Q000276:immunology / Q000378:metabolism; D018106:CD28 Antigens / Q000502:physiology*; D060908:CTLA-4 Antigen; D018946:Chemokine CCL5 / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates; D019410:Interleukin-16 / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D008925:Mites / Q000276:immunology; D016328:NF-kappa B / Q000502:physiology*; D009842:Oligopeptides / Q000494:pharmacology; D009924:Organ Culture Techniques; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism
D000485:Allergens; D019138:Antibodies, Blocking; D015703:Antigens, CD; D039741:Antigens, Dermatophagoides; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018946:Chemokine CCL5; D016207:Cytokines; D006023:Glycoproteins; D018796:Immunoconjugates; D019410:Interleukin-16; D016328:NF-kappa B; D009842:Oligopeptides; C090535:benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal; D000069594:Abatacept; D003907:Dexamethasone